BioLine RX Ltd (BLRX) — Tangible Net Worth Ratio
BioLine RX Ltd (BLRX) has a Tangible Net Worth Ratio of 100.0% as of September 2025. This metric is calculated by deducting intangible assets (ILA0.00) from net assets (ILA19.53 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See BioLine RX Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
BioLine RX Ltd Tangible Net Worth Ratio (2005–2024)
This chart shows how BioLine RX Ltd's Tangible Net Worth Ratio has changed across 19 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 100.0%, reflecting net assets of ILA19.53 Million with intangible assets of ILA0.00 ILA. See BioLine RX Ltd (BLRX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for BioLine RX Ltd (2005–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for BioLine RX Ltd from 2005 to 2024, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see BLRX company net worth.
| Year | Tangible NW Ratio | Net Assets (ILA) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 22.4% | ILA13.46 Million | ILA10.45 Million | ILA38.91 Million | ▲ +34.7 pp |
| 2023 | -12.3% | ILA13.22 Million | ILA14.85 Million | ILA63.92 Million | ▼ -69.3 pp |
| 2022 | 57.0% | ILA50.84 Million | ILA21.89 Million | ILA76.38 Million | ▼ -11.2 pp |
| 2021 | 68.1% | ILA68.09 Million | ILA21.70 Million | ILA81.39 Million | ▲ +66.7 pp |
| 2020 | 1.4% | ILA22.03 Million | ILA21.71 Million | ILA47.29 Million | ▼ -33.0 pp |
| 2019 | 34.4% | ILA33.38 Million | ILA21.89 Million | ILA53.57 Million | ▼ -12.4 pp |
| 2018 | 46.8% | ILA41.32 Million | ILA21.97 Million | ILA56.23 Million | ▼ -39.9 pp |
| 2017 | 86.7% | ILA52.88 Million | ILA7.02 Million | ILA60.97 Million | ▼ -12.8 pp |
| 2016 | 99.5% | ILA35.03 Million | ILA181.00K | ILA38.94 Million | ▼ -0.2 pp |
| 2015 | 99.7% | ILA47.61 Million | ILA152.00K | ILA51.30 Million | ▲ +0.1 pp |
| 2014 | 99.6% | ILA31.77 Million | ILA117.36K | ILA36.17 Million | ▲ +1.8 pp |
| 2013 | 97.8% | ILA11.68 Million | ILA252.12K | ILA19.95 Million | ▼ -0.3 pp |
| 2012 | 98.1% | ILA14.97 Million | ILA284.53K | ILA24.31 Million | ▼ -0.6 pp |
| 2011 | 98.7% | ILA22.53 Million | ILA300.58K | ILA29.34 Million | ▼ -0.3 pp |
| 2010 | 99.0% | ILA131.96 Million | ILA1.35 Million | ILA154.61 Million | ▲ +1.6 pp |
| 2009 | 97.4% | ILA117.94 Million | ILA3.04 Million | ILA159.17 Million | ▲ +1.0 pp |
| 2008 | 96.4% | ILA78.39 Million | ILA2.82 Million | ILA115.73 Million | ▼ -2.5 pp |
| 2007 | 98.9% | ILA183.25 Million | ILA1.98 Million | ILA207.88 Million | ▼ -1.1 pp |
| 2005 | 100.0% | ILA12.77 Million | ILA0.00 | ILA20.59 Million | — |